$TSHA
Taysha Gene Therapies, Inc.

2022 Q3 Form 10-Q Financial Statement

#000156459022029155 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $8.683M $9.867M $11.47M
YoY Change -22.15% -2.59% 39.19%
% of Gross Profit
Research & Development $16.39M $23.12M $1.250M
YoY Change -58.53% -24.56% -77.27%
% of Gross Profit
Depreciation & Amortization $300.0K $300.0K $300.0K
YoY Change 80.72% 252.94% 837.5%
% of Gross Profit
Operating Expenses $25.07M $32.99M $1.250M
YoY Change -50.53% -19.1% -96.1%
Operating Profit -$25.07M -$32.99M -$49.65M
YoY Change -50.53% -19.1% 54.72%
Interest Expense $1.241M $912.0K $849.0K
YoY Change -345.26% 370.1% 1186.36%
% of Operating Profit
Other Income/Expense, Net -$1.233M -$888.0K -$843.0K
YoY Change 476.62% -1377.27%
Pretax Income -$26.31M -$33.87M -$50.11M
YoY Change -48.61% -17.23% 56.5%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$26.31M -$33.87M -$50.11M
YoY Change -48.61% -17.23% 56.48%
Net Earnings / Revenue
Basic Earnings Per Share -$0.64 -$0.84 -$1.32
Diluted Earnings Per Share -$0.64 -$0.84 -$1.313M
COMMON SHARES
Basic Shares Outstanding 41.09M 40.14M 38.17M
Diluted Shares Outstanding 40.94M 40.14M 38.17M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $34.31M $66.24M $96.63M
YoY Change -81.83% -66.44% -57.75%
Cash & Equivalents $34.31M $66.20M $96.60M
Short-Term Investments
Other Short-Term Assets $380.0K $677.0K $941.0K
YoY Change -67.3% -33.23% 12.16%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $43.00M $76.84M $106.9M
YoY Change -78.19% -62.94% -55.39%
LONG-TERM ASSETS
Property, Plant & Equipment $63.95M $61.01M $55.12M
YoY Change 57.7% 80.15% 2104.8%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.245M $1.206M $3.965M
YoY Change -62.49% 74.53% 466.43%
Total Long-Term Assets $68.47M $65.50M $59.09M
YoY Change 56.06% 89.53% 1746.41%
TOTAL ASSETS
Total Short-Term Assets $43.00M $76.84M $106.9M
Total Long-Term Assets $68.47M $65.50M $59.09M
Total Assets $111.5M $142.3M $166.0M
YoY Change -53.76% -41.15% -31.64%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $15.25M $23.97M $22.00M
YoY Change -30.84% 277.14% 436.51%
Accrued Expenses $17.89M $18.99M $26.62M
YoY Change -15.48% -13.84% 78.66%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $33.14M $42.95M $48.62M
YoY Change -23.31% 51.29% 155.88%
LONG-TERM LIABILITIES
Long-Term Debt $37.77M $37.58M $37.39M
YoY Change 35.82%
Other Long-Term Liabilities $3.934M $3.480M $29.25M
YoY Change 30.48% 354.9% 2824.8%
Total Long-Term Liabilities $41.71M $41.06M $66.63M
YoY Change 35.29% 5267.32% 6563.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $33.14M $42.95M $48.62M
Total Long-Term Liabilities $41.71M $41.06M $66.63M
Total Liabilities $100.3M $109.6M $115.3M
YoY Change -0.3% 98.0% 476.26%
SHAREHOLDERS EQUITY
Retained Earnings -$345.9M -$319.6M -$285.8M
YoY Change 86.69% 138.33%
Common Stock $1.000K $1.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $11.13M $32.71M $50.73M
YoY Change
Total Liabilities & Shareholders Equity $111.5M $142.3M $166.0M
YoY Change -53.76% -41.15% -31.64%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$26.31M -$33.87M -$50.11M
YoY Change -48.61% -17.23% 56.48%
Depreciation, Depletion And Amortization $300.0K $300.0K $300.0K
YoY Change 80.72% 252.94% 837.5%
Cash From Operating Activities -$28.66M -$33.21M -$40.80M
YoY Change -10.27% 45.58% 85.18%
INVESTING ACTIVITIES
Capital Expenditures -$2.020M -$7.863M $8.427M
YoY Change -42.32% 161.93% 1478.09%
Acquisitions
YoY Change
Other Investing Activities -$1.000M -$250.0K -$3.000M
YoY Change 100.0% -95.45%
Cash From Investing Activities -$3.020M -$8.113M -$11.43M
YoY Change -24.54% -4.58% 2039.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -258.0K 10.93M -242.0K
YoY Change -100.86%
NET CHANGE
Cash From Operating Activities -28.66M -33.21M -40.80M
Cash From Investing Activities -3.020M -8.113M -11.43M
Cash From Financing Activities -258.0K 10.93M -242.0K
Net Change In Cash -31.93M -30.39M -52.47M
YoY Change 436.06% -2.94% 132.5%
FREE CASH FLOW
Cash From Operating Activities -$28.66M -$33.21M -$40.80M
Capital Expenditures -$2.020M -$7.863M $8.427M
Free Cash Flow -$26.64M -$25.35M -$49.23M
YoY Change -6.32% 27.95% 118.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q4 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
11895000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4620000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7703000
CY2022Q2 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
1500000
CY2022Q2 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
1224000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.14
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.96
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40142403
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37479164
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39163996
us-gaap Net Income Loss
NetIncomeLoss
-83984000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37237115
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
50725000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4249000
CY2022Q2 tsha Payment Of Sales Commissions And Other Offering Costs
PaymentOfSalesCommissionsAndOtherOfferingCosts
392000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11609000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-33873000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32710000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
222872000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4549000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-40926000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186495000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
95383000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9702000
tsha Payment Of Sales Commissions And Other Offering Costs
PaymentOfSalesCommissionsAndOtherOfferingCosts
392000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
11609000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
32710000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
251302000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8143000
us-gaap Net Income Loss
NetIncomeLoss
-72950000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
186495000
us-gaap Profit Loss
ProfitLoss
-83984000
us-gaap Profit Loss
ProfitLoss
-72950000
us-gaap Depreciation
Depreciation
531000
us-gaap Depreciation
Depreciation
117000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
1250000
us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
5500000
us-gaap Share Based Compensation
ShareBasedCompensation
9470000
us-gaap Share Based Compensation
ShareBasedCompensation
8143000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-387000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-194000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-80000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
3282000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
6212000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2382000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
-7958000
tsha Increase Decrease In Accrued Expense And Other Liabilities
IncreaseDecreaseInAccruedExpenseAndOtherLiabilities
15053000
us-gaap Increase Decrease In Due To Related Parties
IncreaseDecreaseInDueToRelatedParties
-8000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-74012000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44851000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
3250000
us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
16290000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
3532000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19540000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-9032000
tsha Payment Of Shelf Registration Costs
PaymentOfShelfRegistrationCosts
227000
tsha Employee Stock Purchase Plan Contributions
EmployeeStockPurchasePlanContributions
321000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11640000
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-1046000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10688000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-82864000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-53883000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
151740000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
251253000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68876000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
197370000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66239000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
197370000
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
2637000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
68876000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
197370000
us-gaap Interest Paid Net
InterestPaidNet
935000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
2722000
tsha Property And Equipment In Accounts Payable And Accrued Expenses
PropertyAndEquipmentInAccountsPayableAndAccruedExpenses
3308000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
606000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
109000
tsha Research And Development License Not Yet Paid
ResearchAndDevelopmentLicenseNotYetPaid
1000000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
26250000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319600000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
66200000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
61011000
CY2022Q2 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
6128000
CY2021Q4 tsha Prepaid Research And Development Contracts
PrepaidResearchAndDevelopmentContracts
5218000
CY2022Q2 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
2934000
CY2021Q4 tsha Prepaid Clinical Trial
PrepaidClinicalTrial
3298000
CY2022Q2 us-gaap Deferred Offering Costs
DeferredOfferingCosts
698000
CY2021Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
545000
CY2022Q2 us-gaap Prepaid Insurance
PrepaidInsurance
108000
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
148000
CY2022Q2 tsha Prepaid Bonus
PrepaidBonus
51000
CY2021Q4 tsha Prepaid Bonus
PrepaidBonus
427000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
677000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
863000
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10596000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
10499000
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
62027000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
51109000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1016000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
499000
CY2021Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.0700
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
50610000
CY2022Q2 us-gaap Depreciation
Depreciation
300000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
100000
CY2022Q2 tsha Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
8918000
CY2021Q4 tsha Accrued License Fees Current
AccruedLicenseFeesCurrent
3500000
CY2021Q4 tsha Accrued Property Plant And Equipment Current
AccruedPropertyPlantAndEquipmentCurrent
2644000
CY2022Q2 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
807000
CY2021Q4 tsha Accrued Clinical Trial Current
AccruedClinicalTrialCurrent
1659000
CY2022Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
439000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1091000
CY2022Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1478000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1491000
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
18986000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
29983000
CY2021Q3 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2026-08-01
CY2021Q3 tsha Percentage Of Prepayment Of Facility
PercentageOfPrepaymentOfFacility
0.075
CY2022Q2 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
3000000.0
CY2021Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2021Q3 tsha Percentage Of Annual Default Interest Rate
PercentageOfAnnualDefaultInterestRate
0.05
us-gaap Interest Expense Long Term Debt
InterestExpenseLongTermDebt
1400000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
6667000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
20000000
CY2022Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
13333000
CY2022Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
40000000
CY2022Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2420000
CY2022Q2 us-gaap Long Term Debt
LongTermDebt
37580000
CY2022Q1 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.35
CY2022Q2 tsha Share Based Compensation Unrecognized Compensation Related To Nonvested Options Awards Granted
ShareBasedCompensationUnrecognizedCompensationRelatedToNonvestedOptionsAwardsGranted
713540
CY2022Q2 tsha Reversal Of Stock Based Compensation Expense
ReversalOfStockBasedCompensationExpense
800000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.84
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.84
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Employee Subscription Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate
0.85
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Discount From Market Price Offering Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPriceOfferingDate
0.15
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Maximum Number Of Shares Per Employee
ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee
1800
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4141000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33873000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40142403
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40142403
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6703054
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2022Q2 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
100000

Files In Submission

Name View Source Status
0001564590-22-029155-index-headers.html Edgar Link pending
0001564590-22-029155-index.html Edgar Link pending
0001564590-22-029155.txt Edgar Link pending
0001564590-22-029155-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gnfmloykm2m3000001.jpg Edgar Link pending
gnfmloykm2m3000002.jpg Edgar Link pending
gnfmloykm2m3000003.jpg Edgar Link pending
gnfmloykm2m3000004.jpg Edgar Link pending
gnfmloykm2m3000005.jpg Edgar Link pending
gnfmloykm2m3000006.jpg Edgar Link pending
gnfmloykm2m3000007.jpg Edgar Link pending
gnfmloykm2m3000008.jpg Edgar Link pending
gnfmloykm2m3000009.jpg Edgar Link pending
gnfmloykm2m3000010.jpg Edgar Link pending
gnfmloykm2m3000011.jpg Edgar Link pending
gnfmloykm2m3000012.jpg Edgar Link pending
gnfmloykm2m3000013.jpg Edgar Link pending
gnfmloykm2m3000014.jpg Edgar Link pending
gnfmloykm2m3000015.jpg Edgar Link pending
gnfmloykm2m3000016.jpg Edgar Link pending
gnfmloykm2m3000017.jpg Edgar Link pending
gnfmloykm2m3000018.jpg Edgar Link pending
gnfmloykm2m3000019.jpg Edgar Link pending
gnfmloykm2m3000020.jpg Edgar Link pending
gnfmloykm2m3000021.jpg Edgar Link pending
gnfmloykm2m3000022.jpg Edgar Link pending
gnfmloykm2m3000023.jpg Edgar Link pending
gnfmloykm2m3000024.jpg Edgar Link pending
gnfmloykm2m3000025.jpg Edgar Link pending
gnfmloykm2m3000026.jpg Edgar Link pending
gnfmloykm2m3000027.jpg Edgar Link pending
gnfmloykm2m3000028.jpg Edgar Link pending
gnfmloykm2m3000029.jpg Edgar Link pending
gnfmloykm2m3000030.jpg Edgar Link pending
gnfmloykm2m3000031.jpg Edgar Link pending
gnfmloykm2m3000032.jpg Edgar Link pending
gnfmloykm2m3000033.jpg Edgar Link pending
gnfmloykm2m3000034.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tsha-10q_20220630.htm Edgar Link pending
tsha-20220630.xsd Edgar Link pending
tsha-20220630_def.xml Edgar Link unprocessable
tsha-10q_20220630_htm.xml Edgar Link completed
tsha-ex311_6.htm Edgar Link pending
tsha-ex312_8.htm Edgar Link pending
tsha-ex321_7.htm Edgar Link pending
tsha-ex322_9.htm Edgar Link pending
tsha-20220630_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
tsha-20220630_cal.xml Edgar Link unprocessable
tsha-20220630_pre.xml Edgar Link unprocessable